drugset / Trial / NCT05486949
Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
RandomizedSequentialOpen-labelOther
Summary
This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of AZD4205 in healthy adult subjects (Part A) and to assess the effect of multiple doses of carbamazepine, a CYP3A4 inducer, on the single dose PK of AZD4205 in healthy adult subjects (Part B).
Timeline
- Start
- 2022-07-27
- Primary completion
- 2022-10-08
- Completion
- 2022-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbamazepine | Small molecule | — | — |
| Subject | Golidocitinib | Small molecule | — | Oral |
| Subject | Itraconazole | Small molecule | — | — |
Indications
No indication recorded.